Skip to main content
Fig. 5 | BMC Research Notes

Fig. 5

From: BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549

Fig. 5

BMS-754807 synergizes with platinum based chemotherapeutics to enhance killing of A549 cells. Lung cancer cells were treated with a combination of BMS-754807 and either cisplatin (a, c) or carboplatin (b, d). Media and drugs were refreshed every 24 h for 72 h, then cell viability was measured using a WST-1 assay. Data illustrated in (a, b) are representative graphs of A549 cells treated BMS-754807 in combination with cisplatin (a) or carboplatin (b). This data is presented as mean ± SEM (n = 4). Combination indices were calculated using Calcusyn software and the data for cisplatin in combination with 0.25 μM of BMS-754807 is presented in (e) while the data for carboplatin in combination with 0.25 μM of BMS-754807 is presented in (f). A549 cells are plotted as black symbols while NCI-H358 cells are plotted as white symbols. The complete list of the interactions of all BMS-754807 concentrations with either cisplatin or carboplatin are presented in Tables 2 and 3

Back to article page